International Kidney Cancer Coalition

Together, we continue to move the field forward, ensuring patients’ voices are heard and their choices respected. @uroweb.org (5/5)

Promoting shared decision-making in kidney cancer care is a collective effort, and we are deeply grateful for the commitment and collaboration for this shared ambition. (4/5)

The session was truly elevated by the perspectives of high-level speakers: Katharina Beyer (NL), Maxine Tran (GB), Steve Pointon (GB), and Riccardo Campi (IT). (3/5)

This year’s programme featured a dynamic session led by Claudia Ungarelli, Vice-Chair of IKCC, focused on ‘Shared Decision-Making in Kidney Cancer: Insights from Global Patient Data & Clinical Practice’. (2/5)

IKCC is delighted to be part of #EAU26 in London, the renowned annual congress of the European Association of Urology. (1/5)

Catch up on all the latest in our newsletter. We’ve featured the ASCO GU Highlights Report, posters and publications from the Global Patient Survey on Kidney Cancer, updates to the My Treatment, My Choice Decision Aid (mRCC), and more. mailchi.mp/ikcc/newslet... #KidneyCancer

Today, 12 March, we join the global community in recognising #WorldKidneyDay. This year’s theme is “Kidney Health for All: Caring for People, Protecting the Planet.”

Find out more and take the kidney quiz: www.worldkidneyday.org/kidney-quiz/

We also look forward to the launch of the EAU–IKCC ‘medical and policy briefing on kidney cancer’ on Sunday 15 March. #EAU26 @uroweb.org (2/2)

IKCC looks forward to meeting you this week in London at the 41st Annual EAU Congress. Don’t miss the round table on ‘Shared Decision-Making in Kidney Cancer’ on Friday 13 March, chaired by Claudia Ungarelli. (1/2)

Photo: Prof Laurence Albiges (IKCC Medical Advisory Board), Dr Eric Jonasch (IKCC Board Chair), Dr Ravindran Kanesvaran (IKCC Medical Advisory Board), and Olivier Exertier (IKCC Executive Director). #KidneyCancer @ascocancer.bsky.social (5/5)

Please find the Highlights Report here: ikcc.org/summary-of-k... (4/5)

Following the Symposium, members of the IKCC Medical Advisory Board created the patient-friendly Highlights Report, which summarises the presentations and includes a Take Home Message section with more in-depth reviews of selected abstracts. (3/5)

As part of the conference programme, Dr Eric Jonasch, IKCC Board Chair made a presentation entitled ‘Emotional Concerns Due to Kidney Cancer (KC) and Disparities in Patient Support Across North America’, which was based on findings from the Global Patient Survey on Kidney Cancer. (2/5)

The IKCC team attended ASCO #GU26 last month in San Francisco to learn about the latest in kidney cancer care and treatment. (1/5)

Tons of respect for patient advocate Joyce Graff and all she has done for the #VHL and #kidneycancer communities globally. Was instrumental with @ikccorg.bsky.social with connections around the world.
Thank you @smartpatients.bsky.social

is a board member of the Working Group on Preventive and Integrative Oncology (AG PRiO) within the German Cancer Association, and is a member of the National Patient Research Council at the National Center for Tumor Diseases (NCT). She is also the CEO of the Kidney Cancer Network Germany. (3/3)

Karin has extensive experience working with patient organisations, and is on the Board of Directors of the WECAN Foundation, serves on the Patient Advisory Committee of the European Cancer Organisation, (2/3)

Join us in welcoming Karin Kastrati as IKCC’s new European Projects Manager! She has been involved with IKCC since 2009, and we are thrilled that she is taking on this new responsibility. (1/3)

Dr Eric Jonasch presented the IKCC poster on "Emotional Concerns Due to Kidney Cancer (KC) and Disparities in Patient Support Across North America (NA): Results from the International Kidney Cancer Coalition (IKCC) Global Patient Survey (GPS)". @ascocancer.bsky.social (2/2)

IKCC is well represented at ASCO #GU26 in San Francisco, including Dr Eric Jonasch, Chair of IKCC, Olivier Exertier, Executive Director, and several members of the Medical Advisory Board. (1/2)

Each year on the last day of February, we pause to recognise Rare Disease Day.

Did you know that the rare genetic condition Von Hippel-Lindau (VHL) is a leading cause of inherited #KidneyCancer?

Share your story with #RareDiseaseDay.

The members of the IKCC Medical Advisory Board met today at ASCO #GU26 in San Francisco to discuss the scientific and medical priorities of IKCC and how to best support kidney cancer patients. Thank you for your important contributions. @ascocancer.bsky.social

Cabozantinib plus nivolumab and ipilimumab in advanced kidney cancer - Action Kidney Cancer The COSMIC-313 study is the first to try using cabozantinib together with two immunotherapy drugs, nivolumab and ipilimumab to treat people with advanced kidney cancer that is considered intermediate-...

Final results from the COSMIC-313 study have been published. A triple combination as a first treatment for advanced #kidneycancer helped people by keeping their cancer under control for longer compared to just the two immunotherapy drugs.
Find out more:
actionkidneycancer.org/cabozantinib...

At the German Cancer Congress last week, Karin Kastrati presented about the CARE1 Pragmatic Clinical Trial. We’re proud to support this important work. #KidneyCancer

Really an excellent example of how country-specific data within the @ikccorg.bsky.social Global Patient Survey can identify variances, gaps, and work to address unmet needs for patients with #kidneycancer

I hear Canada made a similar presentation recently at Canadian research meeting. Good to hear

Thank you to Karin Kastrati for presenting German specific results from the IKCC Global Patient Survey on Kidney Cancer at the German Cancer Congress last week.

They are a registered nonprofit organisation based in Tanzania, dedicated to fighting cancer through compassion, education, advocacy, and innovation.

Learn more on their Facebook page: www.facebook.com/profile.php?... #KidneyCancer (2/2)

A very warm welcome to the new IKCC Partner Organisation, the Feliciana Mshanga Memorial Cancer Foundation! (1/2)

We are excited to welcome Hlas onkologických pacientů (Cancer Patients Voice), a new IKCC Partner Organisation!

They are an umbrella organisation for all types of cancer in the Czech Republic and operate at both the national and regional levels. Learn more: hlaspacientu.cz #KidneyCancer

We’re looking forward to ASCO #GU26 in San Francisco! Eric Jonasch, Chair of the Board, and Olivier Exertier, our Executive Director, will be attending for IKCC. Hope to see you there! www.asco.org/gu